Evidence map›Paper›PMID 37796941›Full record

ArticlePloS one2023

Coarse-grained molecular dynamics-guided immunoinformatics to explain the binder and non-binder classification of Cytotoxic T-cell epitope for SARS-CoV-2 peptide-based vaccine discovery.

Muhammad Yusuf, Wanda Destiarani, Wahyu Widayat, Yosua Yosua, Gilang Gumilar, Angelica Shalfani Tanudireja, Fauzian Giansyah Rohmatulloh, Farhan Azhwin Maulana, Umi Baroroh, Ari Hardianto and 6 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Muhammad YusufFaculty of Mathematics and Natural Sciences, Department of Chemistry, Universitas Padjadjaran, Bandung, West Java, Indonesia.ORCID 0000-0003-1627-1553
Wanda DestiaraniResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung, West Java, Indonesia.ORCID 0000-0003-0968-6830
Wahyu WidayatFaculty of Pharmacy, Pharmaceutical Biology Science, Universitas Mulawarman, Samarinda, East Kalimantan, Indonesia.
Yosua YosuaResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Gilang GumilarResearch Center for Electronics, National Research and Innovation Agency Republic of Indonesia (BRIN), Bandung, West Java, Indonesia.
Angelica Shalfani TanudirejaFaculty of Mathematics and Natural Sciences, Department of Chemistry, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Fauzian Giansyah RohmatullohResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Farhan Azhwin MaulanaResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Umi BarorohResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung, West Java, Indonesia.ORCID 0000-0003-2011-7161
Ari HardiantoFaculty of Mathematics and Natural Sciences, Department of Chemistry, Universitas Padjadjaran, Bandung, West Java, Indonesia.ORCID 0000-0001-6065-5437
Rani MaharaniFaculty of Mathematics and Natural Sciences, Department of Chemistry, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Neni NurainyDepartment of Research and Development, PT Bio Farma, Bandung, West Java, Indonesia.
Acep Riza WijayadikusumahDepartment of Research and Development, PT Bio Farma, Bandung, West Java, Indonesia.
Ryan B RistandiWest Java Provincial Reference Laboratory, Bandung, West Java, Indonesia.
Ines Irene Caterina AtmosukartoLipotek Pty Ltd. The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
Toto SubrotoFaculty of Mathematics and Natural Sciences, Department of Chemistry, Universitas Padjadjaran, Bandung, West Java, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epitope-based peptide vaccine can elicit T-cell immunity against SARS-CoV-2 to clear the infection. However, finding the best epitope from the whole antigen is challenging. A peptide screening using immunoinformatics usually starts from MHC-binding peptide, immunogenicity, cross-reactivity with the human proteome, to toxicity analysis. This pipeline classified the peptides into three categories, i.e., strong-, weak-, and non-binder, without incorporating the structural aspect. For this reason, the molecular detail that discriminates the binders from non-binder is interesting to be investigated. In this study, five CTL epitopes against HLA-A*02:01 were identified from the coarse-grained molecular dynamics-guided immunoinformatics screening. The strong binder showed distinctive activities from the non-binder in terms of structural and energetic properties. Furthermore, the second residue from the nonameric peptide was most important in the interaction with HLA-A*02:01. By understanding the nature of MHC-peptide interaction, we hoped to improve the chance of finding the best epitope for a peptide vaccine candidate.

Indexed as

Antineoplastic AgentsCOVID-19COVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteHLA-A AntigensHumansMolecular Docking SimulationMolecular Dynamics SimulationPeptidesSARS-CoV-2Vaccines, SubunitAntineoplastic AgentsCOVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteHLA-A AntigensPeptidesVaccines, Subunit

Identifiers

PMID37796941
PMCPMC10553366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.